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ABSTRACT
Our vision about breast cancer quality care within a global 
health framework was recently published by Oxford 
University Press. The aim of our work was to reflect on the 
potential to achieve a world- wide improvement in quality 
care, assessing value for money. The population- based 
survival estimates from the CONCORD programme and 
the Breast Health Global Initiative (BHGI) are valuable 
tools for this global effort. Because cancer care delivery 
is becoming unsustainable in many countries assessing 
healthcare value for the cost is becoming increasingly 
important. Recommendations are made for better global 
quality care for patients with breast cancer.
INTRODUCTION
Our vision about breast cancer quality care 
within a global health framework was recently 
published by Oxford University Press. The 
aim of our work was to reflect on the poten-
tial to achieve a world- wide improvement in 
quality care, assessing value for money. The 
population- based survival estimates from 
the CONCORD programme and the Breast 
Health Global Initiative (BHGI) are valuable 
tools for this global effort. Because cancer 
care delivery is becoming unsustainable in 
many countries assessing healthcare value for 
the cost is becoming increasingly important. 
Recommendations are made for better global 
quality care for patients with breast cancer.
Breast cancer is the most common cancer 
among women in 140 of 184 countries. The 
incidence is rising in almost all countries 
and age groups. However, the probability of 
surviving up to 5 years or more since diag-
nosis is increasing and mortality is decreasing 
in high- income countries (HICs). World-
wide variation remains wide, especially in 
low- income and middle- income countries 
(LMICs). The economic burden of breast 
cancer on health systems is growing and 
becoming unsustainable in many countries.
To address breast cancer within a global 
health framework, we published our vision 
about ‘Breast cancer: Global Quality 
care’, a common effort among a broadly 
representative international faculty.1 The 
aim of our work is a reflection on the world-
wide improvement in quality care, assessing 
value for money. The COVID-19 pandemic 
has crystallised the need for a global vision to 
establish effective collaborations to address 
major health dilemmas. The aspiration of this 
editorial is to highlight and put on the inter-
national agenda approaches to provide access 
to high- quality breast cancer care through 
fiscally responsible and sustainable methods 
at a global level.
Quality management on a global scale
Achieving the best quality of clinical care 
requires rigorous quality management. 
In turn, this requires optimal use of inter-
national clinical guidelines, as well as the 
improved organisation of healthcare path-
ways, deployment of population- based cancer 
registries and continuous research to monitor 
the operation of the ‘plan–do–check–act’ 
cycle of the audit.
In all aspects of care, the woman must be 
the centre of focus: she must be informed 
about the decision- making process and 
invited to participate in it. At all stages of 
care, clarity of the goals of treatment for each 
woman is paramount to make decisions and 
actions successful. It is important to under-
stand that some women prefer their clini-
cian to tell them what to do, but many others 
wish to understand their clinical–therapeutic 
pathway to help them feel engaged and 
empowered. These patients should receive 
personalised information and not have to rely 
on the internet to obtain it.2
The integration and use of the multidisci-
plinary meeting (MDM) in routine care for 
patients with cancer is the hallmark of multi-
disciplinary care, and it should ensure that 
the best options for treatment are considered. 
The treatment options for each patient are 
discussed and the most suitable is proposed 
to the patient. A global approach recognises 
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that the options are influenced by regional availability of 
care. After being informed about the possibilities, pref-
erably with all pros and cons, the decision will be made 
in a shared process. Although the management of many 
women with breast cancer is discussed and determined 
during MDMs, such meetings are not mandatory in many 
countries. Biomolecular expert boards as well will become 
more important with the increasing use of genomic tech-
nologies, especially in HICs.
The Breast Health Global Initiative (BHGI) has been 
striving to develop best care approaches to assist in the 
early detection, diagnosis and treatment of women with 
breast cancer in LMICs, but also in underserved commu-
nities in HICs.3 Since 2002, the BHGI has been devel-
oping the approach of ‘resource- stratified’ guidelines. 
This guideline methodology has now been applied by the 
National Comprehensive Cancer Network (NCCN), the 
American Society of Clinical Oncology (ASCO) and by 
the World Health Organisation (WHO).4 High- quality, 
accessible resources are needed for policy- makers and 
healthcare providers to facilitate the effective implemen-
tation of these guidelines in limited- resource settings. 
More recently, BHGI has proposed a ‘phased implemen-
tation’ methodology for translating resource- stratified 
guidelines into clinical practice based on principles of 
implementation research.5
Cancer registries comprise an essential element in 
evaluating cancer control strategies and the quality of 
care, and for setting priorities in public health. Close 
contact between the cancer registry, researchers and 
caregivers will improve the quality and use of the data, 
as well as the ability to understand the relevance of the 
findings.
Quality indicators on a global scale
Optimal patient management is the summation of indi-
vidual high- quality decisions at each step of the breast 
cancer journey. Quality indicators (QI) are typically cate-
gorised as those of structure, process and outcome,6 to 
which we would add value. In examining a specific care 
delivery scenario, a balanced QI panel should be selected, 
based on disease burden and healthcare resources within 
a country, to provide useful information for policy- makers 
to make practical and programmatic decisions. QI panels 
are established by multidisciplinary breast cancer experts, 
working in collaboration with patient advocates, taking 
into account the difficulties in determining the right 
standard.7
Structure indicators
These are designed to measure whether healthcare facil-
ities and equipment are adequately organised to deliver 
appropriate and timely care to the target population. 
The organisation of a MDM, the pathway to make a deci-
sion, the availability of specialised equipment and trained 
personnel are examples of such indicators.
Process indicators
These measure how patients move through the early 
detection, diagnosis and treatment pathways, as reflected 
both by timeliness and by the degree of adherence to 
clinical guidelines, including justified deviations, which 
can improve the woman’s oncological outcomes or her 
quality of life. Process indicators tell us whether each step 
of the care pathway performs as desired.
Outcome indicators
These, such as recurrence and survival, and patient- 
reported outcome measures (PROMs), are perhaps 
the most relevant from a global health perspective, but 
hardest to define.
Measures of recurrence and survival are reliable only 
if the numerator and denominator refer to the same 
patient populations and if large cohorts are followed over 
adequate periods of time. Long- term outcome measures 
are often influenced by many variables, making the assign-
ment of responsibility of benefit or harm difficult. Global 
surveillance of breast cancer survival trends is the best 
example of real- world data to make an impact on health 
policy. The population- based survival estimates from the 
CONCORD programme reflect the overall effectiveness 
of health systems and help to inform strategic policy- 
making. The aim of the CONCORD programme is to 
monitor cancer survival trends worldwide and explain the 
reasons for the wide inequalities.8 The most recent cycle 
of the CONCORD programme (CONCORD-3) includes 
data from 322 cancer registries in 71 countries, covering 
a total population of almost 1 billion in 2014.9 Health 
ministers in these countries now have access to interna-
tionally comparable cancer survival estimates. Since 2017, 
the survival estimates from CONCORD have become one 
of the key indicators of health system performance in 
the OECD Health at a Glance publication. In contrast to 
clinical trials, which aim to achieve the highest possible 
survival in a group of patients selected by age, stage and 
lack of comorbidity, survival estimated from real- world 
data, obtained from population- based cancer registries, 
reflects the average survival achieved by all patients with 
cancer, and therefore, the overall quality of the health 
system in managing cancer from early diagnosis to treat-
ment and final outcome. Breast cancer survival up to 5 
years after diagnosis continues to increase. In many coun-
tries, 5- year survival has reached 85% or more, but global 
variation remains wide.
The collection of PROMs is becoming mandatory in 
developing countries, where value- based healthcare is 
recognized. Their aim is to monitor the health- related 
quality of life as viewed by the patients themselves 
and to reduce healthcare costs by avoiding the use 
of unnecessary treatments. In addition, they support 
informed decision making and improve healthcare 
quality by enabling comparison of outcome data 
between providers. The implementation of standard 
sets of PROMs, such as those proposed by the Interna-
tional Consortium for Health Outcomes Measurement, 
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requires resources and dedicated personnel.10 For 
countries where this level of scrutiny is not feasible, 
alternatives need to be sought.
ASSESSING HEALTHCARE VALUE FOR COSTS
Breast cancer costs are increasing due to rising numbers 
of patients and increasing treatment costs. These costs 
account for 13% of the total cancer- related expendi-
ture in the EU. Medication represents 20% of the total 
economic burden of breast cancer in the EU.11 So, the 
optimal use of limited resources is increasingly impor-
tant in all countries. The assessment of the value of new 
cancer treatments based on a clinical benefit is becoming 
very important in breast cancer today. The ESMO Magni-
tude of Clinical Benefit Scale and ASCO Framework of 
Value are valuable tools. It is interesting to note the curvi-
linear relationship between 5- year net survival and gross 
domestic product (GDP), which reaches an asymptote 
around a GDP of US$30 000 to US$35 000 per capita. 
Above a certain level of growth, survival levels appear to 
plateau (figure 1). There is a more linear relationship 
between 5- year survival and total national expenditure on 
health as a proportion of GDP.
Overdiagnosis and overtreatment are important issues 
in HICs but are less relevant in LMICs. After the surgical 
revolution of breast conservation,12 oncoplastic surgery13 
and sentinel node biopsy,14 the recent use of hypofrac-
tionation of radiotherapy15 simplified local treatment. In 
addition, the introduction of gene expression profiling in 
endocrine positive breast cancer and the new strategies 
of combining and optimising HER2- targeted therapies 
could potentially improve outcomes but may in essence 
allow de- escalation of treatment in many patients sparing 
patients unnecessary treatments and their related toxic-
ities.16 17 Healthcare value for money must be ensured 
when determining which services are included in benefit 
packages. Since recent projections suggest that more 
than 60% of women will soon be diagnosed over the age 
of 70 years, geriatric assessment can provide personalised, 
high- quality care for many of them.18
RECOMMENDATIONS
Cancer registries
Population- based cancer registries provide insight into 
the burden of cancer by recording data for each patient 
diagnosed with a malignancy in the territory that they 
cover. Information from population- based cancer regis-
tries on trends in socioeconomic, geographic or racial 
differences in incidence and survival can be used to 
plan and refine public health policy. Similar problems 
that arise in all countries suggest common solutions. 
However, specific differences between countries suggest 
the need to look more closely at subpopulations within 
each country or region, to understand better how to 
optimise breast cancer care for underserved women 
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Figure 1 Breast cancer: globaldistribution of age- standardised 5- year net survival (%) in adult women (aged15-99 years) 
diagnosed during 2005-2009, by country, gross domestic product(US$ Purchasing Power Parity, PPP per capita) and total 
national expenditure onhealth. Data source: CONCORD programme.
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information on stage, tumour biomarkers, treatment 
and recurrent disease, can also help to evaluate guide-
line implementation and to measure the impact of new 
treatment regimens in daily practice. Cancer registries 
need long- term political, legal and financial support to 
do their job.19
Multidisciplinary meeting
Today, breast cancer care requires an integrated team 
approach by clinicians within a breast unit. High- quality 
management of breast cancer should be part of daily prac-
tice along with routine use of the MDM. Teleoncology 
may be helpful, but it requires efficient technologies and 
optimal presenter preparation. Human resources and 
technological barriers must be addressed to realise its full 
impact, especially in developing countries.20
Prevention and early diagnosis
Preventive actions include a reduction in alcohol 
consumption and an increase in physical activity. However, 
while prevention is key, it is also long term; therefore, 
early diagnosis and access to effective treatment remain 
crucial. Public awareness is more important in LMICs, 
whereas screening is more effective in HICs.
Quality
Quality management should be part of the daily practice 
of each breast centre and can be enhanced by accredita-
tion programmes and continuing education for doctors, 
nurses and the entire breast cancer team.21 The identi-
fication of QIs for each specific diagnostic and treat-
ment area is mandatory, including both minimal and 
ideal requirements. Clarity of the goals of treatment 
and informing patients at all stages of the disease are 
paramount to decide the actions to be taken. Guide-
lines adherence is associated with improved patient 
outcomes.
Primary care
A strong primary care presence is necessary to guide 
patients through the entire care pathway. The shortage 
of general practitioners around the world requires 
a strategy addressing the needs of each country and 
not the preferences of the medical faculty. A system in 
which at least 50% of the physicians are primary care 
doctors will probably have better health outcomes and 
lower costs, especially in LMICs.22 The global shortfall 
in the nursing workforce will also result in worsening 
healthcare systems.
Cost
Breast cancer costs are increasing due to rising patient 
numbers coupled with increasing treatment cost. 
Accessibility and health coverage are more important 
in LMICs while uniform distribution of healthcare 
burdens HICs. Health economics can assist decision 
makers to adopt and reimburse care that is affordable 
and efficient. WHO provides a list of minimal required 
cancer medicines for all patients worldwide. The only 
viable road is to agree on a broad framework, encom-
passing both patient values and societal values.
Executives
Government, local authorities and national cancer plans 
are the most important components to address the cancer 
burden and coordinate the required actions. Encourage-
ment of national attention to breast cancer care will be 
necessary to achieve optimal outcomes. In LMICs, health-
care networks should be defined to connect surrounding 
areas to centres of excellence. Accessibility and health 
coverage are particularly important in these countries. 
Comprehensive financial protection with social health 
insurance programmes and tax- based financing systems 
must be promoted in both LMICs and HICs.
Research
A new model - for clinical breast cancer research is 
needed. It should be based on the latest understanding of 
cancer biology, ensuring that women with breast cancer in 
all countries can benefit from the latest advances in diag-
nosis and treatment. More clinical trials are needed to 
assess new surgical and radiotherapy regimens for breast 
cancer. Epidemiological studies using population- based 
cancer registry data are also needed to evaluate whether 
the benefits from clinical trials have been made available 
to all patients with cancer and to obtain new knowledge 
on the effects of interventions on the daily life of patients 
with breast cancer, such as elderly patients who are often 
excluded from clinical trials. Clear endpoints must 
be defined to consider the patients’ needs, including 
PROMs.23
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